Device Labeling Survey Shows Risk/Benefit Data Of Utmost Interest To Users
This article was originally published in The Gray Sheet
Device manufacturers should cooperate with FDA in developing a model of presenting complete device information that would allow practitioners to dispense safety and efficacy information more effectively to patients, the Center for Devices and Radiological Health recommends.
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.